Home > Boards > US Listed > Medical - Drugs > Abbvie (ABBV)

06:38am 09/26/2019

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
stockguard Member Profile
 
Followed By 15
Posts 1,258
Boards Moderated 0
Alias Born 07/09/05
160x600 placeholder
Form 8.3 - [Allergan Plc] Dow Jones News - 11/14/2019 9:49:00 AM
Form 8.3 - Allergan Plc Dow Jones News - 11/13/2019 10:23:00 AM
Credit Markets: AbbVie's $30 Billion Sale of Debt Draws Strong Demand -- WSJ Dow Jones News - 11/13/2019 3:02:00 AM
AbbVie Prices $30 Billion of Senior Unsecured Notes PR Newswire (US) - 11/12/2019 9:45:00 PM
AbbVie Sells $30 Billion of Bonds -- 2nd Update Dow Jones News - 11/12/2019 6:39:00 PM
AbbVie Prepares Large Bond Sale -- Update Dow Jones News - 11/12/2019 3:34:00 PM
AbbVie Prepares Large Bond Sale to Fund Allergan Purchase Dow Jones News - 11/12/2019 1:32:00 PM
New Positive Data for RINVOQ™ (upadacitinib) on Signs and Symptoms in Patients with Ankylosing Spondylitis Presented at 201... PR Newswire (US) - 11/12/2019 11:15:00 AM
Form 8.3 - Allergan Plc Dow Jones News - 11/12/2019 10:19:00 AM
Form 8.3 - [Allergan Plc] Dow Jones News - 11/11/2019 9:56:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/8/2019 5:15:21 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 11/8/2019 12:15:16 PM
Form 8.3 - Allergan Plc Dow Jones News - 11/8/2019 10:01:00 AM
J&J's Janssen Gets Health Canada OK for Expanded Imbruvica Use Dow Jones News - 11/8/2019 9:17:00 AM
J&J's Janssen Seeks FDA OK for Expanded Imbruvica Use Dow Jones News - 11/8/2019 8:27:00 AM
AbbVie Submits Supplemental New Drug Application to U.S. FDA For IMBRUVICA® (ibrutinib) in Combination with Rituximab for th... PR Newswire (US) - 11/8/2019 7:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/8/2019 6:07:52 AM
AbbVie Announces Results of Early Participation in Exchange Offers and Consent Solicitations for Allergan Notes PR Newswire (US) - 11/7/2019 8:41:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/7/2019 9:18:45 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/6/2019 3:31:31 PM
AbbVie Announces Launch of Private Offering of Senior Unsecured Notes PR Newswire (US) - 11/6/2019 3:06:00 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/6/2019 10:18:15 AM
Form 8.3 - [AbbVie. Inc] Dow Jones News - 11/6/2019 9:58:00 AM
Form 8.3 - [Allergan Plc] Dow Jones News - 11/6/2019 9:45:00 AM
Form 8.3 - [Allergan Plc] Dow Jones News - 11/5/2019 10:10:00 AM
stockguard   Thursday, 09/26/19 02:32:51 PM
Re: None
Post # of 511 
06:38am 09/26/2019
AbbVie, Allergan rating change at Citi
Citi upgrades AbbVie to Buy, sees 'significant' value from Allergan deal. Citi analyst Andrew Baum upgraded AbbVie to Buy from Neutral and raised his price target for the shares to $90 from $87. The analyst believes AbbVie will "extract significant shareholder value" from Allergan's (AGN) franchises given its "strong commercial focus and patient/physician centricity." Further, within AbbVie's organic portfolio, Baum continues to think the market underappreciates the revenue potential.



Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist